Clinical trial · Interventional
Utility of a Mobile Application for Young Women With Breast Cancer
NCT07009093CI-TRIAL-00118950recruitingN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 16, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260916-000001
Summary
Brief summary (as posted)
This study aims to evaluate the use of mobile technology as a communication tool among patients with breast cancer and measured its effect on patient-reported cancer-related distress, specifically focusing on young women as they often face unique challenges.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Cancer Distress | Breast Neoplasm | PROBABILISTIC | 0.70 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Mighty Pro Application | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Access to the Mighty Pro Application
- description
- Participants will be given access to the Mighty Pro Application for 12 months.
- interventionNames
- Other: Mighty Pro Application
- type
- NO_INTERVENTION
- label
- No Access to the Mighty Pro Application
- description
- Participants will not be given access to the Mighty Pro Application.
Primary outcomes (2)
- measure
- Stage 1: Feasibility of Implementation of Mighty Pro App
- timeFrame
- 26 Weeks
- description
- Binary variable indicating if at least one encounter with the application occurred for at least 80% of the weeks during the observation period. At the Participant level, the scale is either 0 (less than 80% utilization of the Mighty Pro App at least once per week during the 26-week observation period) or 1 (80% or greater utilization of the Mighty Pro App App at least once per week during the the 26-week observation period).
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Ability to understand and willingness to sign an IRB-approved informed consent * Age ≥ 18 and ≤ 45 years at the time of consent * Female * Established patient at Atrium Health Wake Forest Baptist Comprehensive Cancer Center (AHWFBCCC) * Histological confirmation of any type and stage (0-IV) of breast cancer * Screening (baseline) NCCN Distress Thermometer score ≥ 4 * Access to a mobile device for trial purposes and an active email address * Ability to read and understand the English language. NOTE: The Mighty Pro Application is available in English only. * As determined by the enrolling Investigator, ability of the participant to understand and comply with study procedures for the entire length of the study Exclusion Criteria: \- None
References
Publications (0)
Data not yet available
No reference posted for this study.